The term “patent cliff” has served as a powerful and often terrifying metaphor in the pharmaceutical industry. It paints a […]

The High-Stakes Gamble: Why Late-Stage Drug Development Is a Ticking Time Bomb For investors, the biopharmaceutical pipeline represents both a

For seasoned professionals in intellectual property (IP), research and development (R&D), and business development, the simple question, “What is the

The story of generic drugs is often told in simple terms: they are the affordable alternatives that save patients and

In pharmaceutical and biotechnology innovation patent litigation is not merely a legal hurdle; it is a multi-million-dollar crucible where market

Welcome. If you’re a professional in the pharmaceutical and biotech space, you understand that the conversation about generic drugs goes

Introduction The branded pharmaceutical industry, long a bastion of high-margin innovation, stands at a precipice. It is caught in the

Introduction: The 20-Year Illusion and the Race for Effective Patent Life In pharmaceutical innovation the 20-year patent term is both

The market value of a pharmaceutical company is the discounted sum of its future cash flows, and those cash flows